ANIP · ANI Pharmaceuticals Inc.
View on chartInsiders & Stakes
| MERIDIAN VENTURE PARTNERS II LP 10% Owner | ▼ Sell | Open Market | 1,819,259 Shares held | 8/16/2023 | View profile |
| Nikhil Lalwani PRESIDENT & CEO | ▼ Sell | Open Market | 339,089 Shares held | 9/15/2026 | View profile |
| Stephen P. Carey SVP & CFO | ▼ Sell | Open Market | 168,993 Shares held | 9/29/2026 | View profile |
| Marken James G. SVP OPS & PROD DEV | ▼ Sell | Tax Withholding | 117,829 Shares held | 6/7/2024 | View profile |
| Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | ▲ Buy | Grant | 101,056 Shares held | 2/26/2026 | View profile |
| Christopher Mutz HEAD OF RARE DISEASE | ▼ Sell | Open Market | 91,309 Shares held | 3/13/2026 | View profile |
| Ori Gutwerg SVP, GENERICS | ▼ Sell | Open Market | 75,534 Shares held | 8/10/2026 | View profile |
| Chad Gassert SVP - CORP. DEV. & STRATEGY | ▼ Sell | Tax Withholding | 74,916 Shares held | 2/28/2026 | View profile |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | ▼ Sell | Open Market | 73,924 Shares held | 9/14/2026 | View profile |
| Krista Davis SVP, CHIEF HR OFFICER | ▼ Sell | Open Market | 51,946 Shares held | 3/9/2026 | View profile |
| Brown Robert E. JR | ▲ Buy | Grant | 49,021 Shares held | 4/27/2022 | View profile |
| Thomas Haughey Director | ▼ Sell | Open Market | 38,878 Shares held | 6/8/2026 | View profile |
| NASH DAVID | ▲ Buy | Grant | 38,561 Shares held | 5/23/2023 | View profile |
| Patrick D. Walsh Director | ▼ Sell | Open Market | 38,432 Shares held | 5/13/2026 | View profile |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | ▼ Sell | Open Market | 38,271 Shares held | 5/12/2026 | View profile |
| Renee P. Tannenbaum Director | ▲ Buy | Grant | 29,514 Shares held | 5/21/2026 | View profile |
| Antonio R. Pera Director | ▲ Buy | Grant | 27,017 Shares held | 5/21/2026 | View profile |
| Jeanne Thoma Director | ▼ Sell | Open Market | 26,762 Shares held | 9/11/2026 | View profile |
| Matthew J. Leonard Director | ▲ Buy | Grant | 11,221 Shares held | 5/21/2026 | View profile |
| Gosebruch Henry O Director | ▲ Buy | Grant | 6,662 Shares held | 8/19/2026 | View profile |
Transaction History
| Stephen P. Carey | ▼ Sell | Open Market | 2,850 | $208K | 9/29/2026 |
| Nikhil Lalwani | ▼ Sell | Open Market | 5,400 | $383K | 9/15/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $35K | 9/14/2026 |
| Jeanne Thoma | ▼ Sell | Open Market | 1,000 | $72K | 9/11/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 2,850 | $207K | 8/31/2026 |
| Nikhil Lalwani | ▼ Sell | Open Market | 5,400 | $401K | 8/25/2026 |
| Gosebruch Henry O | ▲ Buy | Grant | 6,662 | $0 | 8/19/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $38K | 8/13/2026 |
| Ori Gutwerg | ▼ Sell | Open Market | 3,162 | $243K | 8/10/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 2,850 | $232K | 7/29/2026 |
| Meredith Cook | ▼ Sell | Tax Withholding | 2,466 | $195K | 7/18/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $41K | 7/13/2026 |
| Stephen P. Carey | ▲ Buy | Option Exercise | 3,313 | $164K | 7/2/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 3,313 | $285K | 7/2/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 2,850 | $240K | 6/29/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $41K | 6/12/2026 |
| Thomas Haughey | ▼ Sell | Open Market | 2,000 | $162K | 6/8/2026 |
| Stephen P. Carey | ▲ Buy | Option Exercise | 3,312 | $164K | 6/5/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 3,312 | $265K | 6/5/2026 |
| Jeanne Thoma | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 |
| Renee P. Tannenbaum | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 |
| Antonio R. Pera | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 |
| Matthew J. Leonard | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 |
| Thomas Haughey | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 |
| Patrick D. Walsh | ▼ Sell | Open Market | 10,000 | $806K | 5/13/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $39K | 5/13/2026 |
| Thomas Andrew Rowland | ▼ Sell | Open Market | 459 | $36K | 5/12/2026 |
| Ori Gutwerg | ▼ Sell | Open Market | 2,772 | $220K | 5/12/2026 |
| Patrick D. Walsh | ▼ Sell | Open Market | 3,973 | $321K | 5/11/2026 |
| Nikhil Lalwani | ▼ Sell | Open Market | 55,000 | $4.3M | 5/11/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $39K | 4/13/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 3,162 | $227K | 3/13/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $36K | 3/13/2026 |
| Thomas Andrew Rowland | ▼ Sell | Open Market | 4,772 | $357K | 3/11/2026 |
| Krista Davis | ▼ Sell | Open Market | 5,087 | $377K | 3/9/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 3,602 | $267K | 3/9/2026 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 3,314 | $245K | 3/7/2026 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 5,150 | $381K | 3/7/2026 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 3,314 | $245K | 3/7/2026 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 17,060 | $1.3M | 3/7/2026 |
| Krista Davis | ▼ Sell | Open Market | 1,485 | $111K | 3/6/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 2,121 | $157K | 3/6/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 4,000 | $302K | 3/5/2026 |
| Stephen P. Carey | ▲ Buy | Option Exercise | 3,312 | $164K | 3/5/2026 |
| Stephen P. Carey | ▼ Sell | Open Market | 3,312 | $250K | 3/5/2026 |
| Ori Gutwerg | ▼ Sell | Open Market | 2,060 | $158K | 3/3/2026 |
| Patrick D. Walsh | ▼ Sell | Open Market | 6,000 | $445K | 3/3/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 417 | $31K | 3/2/2026 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 628 | $46K | 2/28/2026 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 2,221 | $164K | 2/28/2026 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 12,217 | $903K | 2/28/2026 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 2,221 | $164K | 2/28/2026 |
| Chad Gassert | ▼ Sell | Tax Withholding | 2,221 | $164K | 2/28/2026 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,555 | $115K | 2/28/2026 |
| Meredith Cook | ▼ Sell | Tax Withholding | 1,555 | $115K | 2/28/2026 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 2,773 | $205K | 2/28/2026 |
| Muthusamy Shanmugam | ▲ Buy | Grant | 11,116 | $858K | 2/26/2026 |
| Thomas Andrew Rowland | ▲ Buy | Grant | 6,021 | $465K | 2/26/2026 |
| Christopher Mutz | ▲ Buy | Grant | 21,306 | $1.6M | 2/26/2026 |
| Nikhil Lalwani | ▲ Buy | Grant | 75,592 | $5.8M | 2/26/2026 |
| Ori Gutwerg | ▲ Buy | Grant | 12,969 | $1.0M | 2/26/2026 |
| Chad Gassert | ▲ Buy | Grant | 11,116 | $858K | 2/26/2026 |
| Krista Davis | ▲ Buy | Grant | 10,810 | $834K | 2/26/2026 |
| Meredith Cook | ▲ Buy | Grant | 13,895 | $1.1M | 2/26/2026 |
| Stephen P. Carey | ▲ Buy | Grant | 22,233 | $1.7M | 2/26/2026 |
| Krista Davis | ▼ Sell | Open Market | 1,730 | $135K | 2/20/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 5,323 | $415K | 2/20/2026 |
| Krista Davis | ▼ Sell | Open Market | 2,084 | $162K | 2/19/2026 |
| Chad Gassert | ▼ Sell | Tax Withholding | 1,717 | $133K | 2/14/2026 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 485 | $38K | 2/14/2026 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 2,403 | $186K | 2/14/2026 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 10,298 | $797K | 2/14/2026 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 1,888 | $146K | 2/14/2026 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,290 | $100K | 2/14/2026 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 2,448 | $189K | 2/14/2026 |
| Meredith Cook | ▼ Sell | Tax Withholding | 1,779 | $138K | 2/14/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $38K | 2/13/2026 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 566 | $43K | 2/12/2026 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 3,173 | $243K | 2/12/2026 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 11,688 | $896K | 2/12/2026 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 1,775 | $136K | 2/12/2026 |
| Chad Gassert | ▼ Sell | Tax Withholding | 1,608 | $123K | 2/12/2026 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,180 | $91K | 2/12/2026 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 2,829 | $217K | 2/12/2026 |
| Christopher Mutz | ▼ Sell | Open Market | 7,032 | $538K | 2/12/2026 |
| Meredith Cook | ▼ Sell | Tax Withholding | 1,534 | $118K | 2/12/2026 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 4,267 | $325K | 2/11/2026 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 30,659 | $2.3M | 2/11/2026 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 4,546 | $347K | 2/11/2026 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 1,762 | $134K | 2/11/2026 |
| Muthusamy Shanmugam | ▼ Sell | Tax Withholding | 2,898 | $221K | 2/11/2026 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 5,503 | $420K | 2/11/2026 |
| Meredith Cook | ▼ Sell | Tax Withholding | 3,011 | $230K | 2/11/2026 |
| Krista Davis | ▼ Sell | Tax Withholding | 3,017 | $230K | 2/11/2026 |
| Chad Gassert | ▼ Sell | Tax Withholding | 4,269 | $326K | 2/11/2026 |
| Meredith Cook | ▼ Sell | Open Market | 500 | $42K | 1/13/2026 |
| Krista Davis | ▼ Sell | Open Market | 1,622 | $134K | 12/18/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $33K | 12/12/2025 |
| Renee P. Tannenbaum | ▼ Sell | Open Market | 1,800 | $146K | 12/5/2025 |
| Patrick D. Walsh | ▼ Sell | Open Market | 8,643 | $751K | 11/13/2025 |
| Patrick D. Walsh | ▼ Sell | Gift | 3,000 | $0 | 11/13/2025 |
| Chad Gassert | ▼ Sell | Open Market | 94 | $8K | 11/13/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $35K | 11/13/2025 |
| Chad Gassert | ▼ Sell | Open Market | 14,642 | $1.3M | 11/12/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $36K | 10/13/2025 |
| Krista Davis | ▼ Sell | Open Market | 1,000 | $98K | 9/19/2025 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,710 | $167K | 9/12/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $39K | 9/12/2025 |
| Antonio R. Pera | ▼ Sell | Open Market | 7,292 | $692K | 9/3/2025 |
| Matthew J. Leonard | ▼ Sell | Open Market | 2,528 | $229K | 8/25/2025 |
| Krista Davis | ▼ Sell | Open Market | 1,763 | $161K | 8/22/2025 |
| Muthusamy Shanmugam | ▼ Sell | Open Market | 52,988 | $4.8M | 8/21/2025 |
| Muthusamy Shanmugam | ▼ Sell | Open Market | 47,012 | $4.2M | 8/20/2025 |
| Antonio R. Pera | ▼ Sell | Open Market | 5,421 | $486K | 8/20/2025 |
| Jeanne Thoma | ▼ Sell | Open Market | 6,865 | $616K | 8/18/2025 |
| Jeanne Thoma | ▼ Sell | Open Market | 14,675 | $1.3M | 8/18/2025 |
| Matthew J. Leonard | ▼ Sell | Open Market | 6,937 | $612K | 8/18/2025 |
| Chad Gassert | ▼ Sell | Open Market | 20,000 | $1.7M | 8/15/2025 |
| Patrick D. Walsh | ▼ Sell | Open Market | 9,000 | $801K | 8/15/2025 |
| Muthusamy Shanmugam | ▼ Sell | Open Market | 52,990 | $4.6M | 8/15/2025 |
| Muthusamy Shanmugam | ▼ Sell | Open Market | 47,010 | $4.2M | 8/14/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $36K | 8/13/2025 |
| Thomas Andrew Rowland | ▼ Sell | Open Market | 4,975 | $426K | 8/12/2025 |
| Nikhil Lalwani | ▼ Sell | Open Market | 56,960 | $4.9M | 8/12/2025 |
| Ori Gutwerg | ▼ Sell | Open Market | 5,873 | $508K | 8/12/2025 |
| Stephen P. Carey | ▲ Buy | Option Exercise | 50,000 | $2.3M | 8/12/2025 |
| Stephen P. Carey | ▼ Sell | Open Market | 50,000 | $4.3M | 8/12/2025 |
| Thomas Haughey | ▼ Sell | Open Market | 19,341 | $1.7M | 8/12/2025 |
| Meredith Cook | ▼ Sell | Tax Withholding | 2,071 | $137K | 7/18/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $26K | 7/14/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $25K | 6/13/2025 |
| Matthew J. Leonard | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Antonio R. Pera | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Renee P. Tannenbaum | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Patrick D. Walsh | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Thomas Haughey | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Jeanne Thoma | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 |
| Ori Gutwerg | ▼ Sell | Open Market | 881 | $53K | 5/15/2025 |
| Christopher Mutz | ▼ Sell | Open Market | 4,000 | $242K | 5/14/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $25K | 5/13/2025 |
| Muthusamy Shanmugam | ▼ Sell | Open Market | 700 | $54K | 5/9/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $28K | 4/14/2025 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 6,210 | $399K | 3/23/2025 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 17,455 | $1.1M | 3/23/2025 |
| Krista Davis | ▼ Sell | Open Market | 1,866 | $121K | 3/19/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $25K | 3/13/2025 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 2,874 | $174K | 3/7/2025 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 3,314 | $201K | 3/7/2025 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 5,150 | $312K | 3/7/2025 |
| Krista Davis | ▼ Sell | Open Market | 1,000 | $61K | 3/7/2025 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 17,060 | $1.0M | 3/7/2025 |
| Ori Gutwerg | ▲ Buy | Option Exercise | 300 | $9K | 3/5/2025 |
| Ori Gutwerg | ▼ Sell | Open Market | 300 | $18K | 3/5/2025 |
| Ori Gutwerg | ▼ Sell | Open Market | 5,084 | $305K | 3/5/2025 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 627 | $39K | 2/28/2025 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 1,275 | $79K | 2/28/2025 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 12,216 | $756K | 2/28/2025 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 1,570 | $97K | 2/28/2025 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 1,861 | $115K | 2/28/2025 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,099 | $68K | 2/28/2025 |
| Meredith Cook | ▼ Sell | Tax Withholding | 1,099 | $68K | 2/28/2025 |
| Krista Davis | ▼ Sell | Open Market | 1,000 | $60K | 2/21/2025 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 1,184 | $70K | 2/15/2025 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 1,167 | $69K | 2/15/2025 |
| Meredith Cook | ▼ Sell | Tax Withholding | 1,434 | $84K | 2/14/2025 |
| Stephen P. Carey | ▼ Sell | Tax Withholding | 1,730 | $102K | 2/14/2025 |
| Nikhil Lalwani | ▼ Sell | Tax Withholding | 7,799 | $460K | 2/14/2025 |
| Ori Gutwerg | ▼ Sell | Tax Withholding | 1,426 | $84K | 2/14/2025 |
| Krista Davis | ▼ Sell | Tax Withholding | 1,196 | $70K | 2/14/2025 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 582 | $34K | 2/14/2025 |
| Christopher Mutz | ▼ Sell | Tax Withholding | 1,473 | $87K | 2/14/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $24K | 2/13/2025 |
| Chad Gassert | ▲ Buy | Grant | 14,362 | $0 | 2/12/2025 |
| Nikhil Lalwani | ▲ Buy | Grant | 91,399 | $0 | 2/12/2025 |
| Nikhil Lalwani | ▲ Buy | Grant | 60,932 | $0 | 2/12/2025 |
| Ori Gutwerg | ▲ Buy | Grant | 15,668 | $0 | 2/12/2025 |
| Thomas Andrew Rowland | ▲ Buy | Grant | 7,834 | $0 | 2/12/2025 |
| Christopher Mutz | ▲ Buy | Grant | 16,538 | $0 | 2/12/2025 |
| Christopher Mutz | ▲ Buy | Grant | 24,808 | $0 | 2/12/2025 |
| Thomas Andrew Rowland | ▲ Buy | Grant | 5,222 | $0 | 2/12/2025 |
| Muthusamy Shanmugam | ▲ Buy | Grant | 14,362 | $0 | 2/12/2025 |
| Stephen P. Carey | ▲ Buy | Grant | 16,538 | $0 | 2/12/2025 |
| Chad Gassert | ▲ Buy | Grant | 9,574 | $0 | 2/12/2025 |
| Stephen P. Carey | ▲ Buy | Grant | 24,808 | $0 | 2/12/2025 |
| Krista Davis | ▲ Buy | Grant | 8,704 | $0 | 2/12/2025 |
| Krista Davis | ▲ Buy | Grant | 13,057 | $0 | 2/12/2025 |
| Meredith Cook | ▲ Buy | Grant | 16,974 | $0 | 2/12/2025 |
| Meredith Cook | ▲ Buy | Grant | 11,316 | $0 | 2/12/2025 |
| Muthusamy Shanmugam | ▲ Buy | Grant | 9,574 | $0 | 2/12/2025 |
| Ori Gutwerg | ▲ Buy | Grant | 10,444 | $0 | 2/12/2025 |
| Meredith Cook | ▼ Sell | Open Market | 400 | $22K | 1/13/2025 |
| Stephen P. Carey | ▼ Sell | Open Market | 7,500 | $418K | 12/17/2024 |
| Meredith Cook | ▼ Sell | Open Market | 250 | $14K | 12/13/2024 |
| Krista Davis | ▼ Sell | Open Market | 1,000 | $60K | 12/11/2024 |
| Nikhil Lalwani | ▲ Buy | Option Exercise | 30,000 | $870K | 11/26/2024 |
| Nikhil Lalwani | ▼ Sell | Open Market | 30,000 | $1.7M | 11/26/2024 |
| Nikhil Lalwani | ▼ Sell | Open Market | 3,481 | $203K | 11/26/2024 |
| Thomas Andrew Rowland | ▼ Sell | Tax Withholding | 867 | $49K | 11/15/2024 |
| Christopher Mutz | ▼ Sell | Open Market | 6,500 | $375K | 11/15/2024 |
| Meredith Cook | ▼ Sell | Open Market | 250 | $15K | 11/13/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results
ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results. ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.